

FOI 3718

1st May 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:

Response:

- Abrocitinib - 7
- Acitretin -data not held*
- Alitretinoin -data not held*
- Azathioprine -data not held*
- Baricitinib - <5
- Ciclosporin -data not held*
- Dupilumab -163
- Lebrikizumab - <5**
- Methotrexate –data not held*
- Mycophenolate mofetil -data not held*
- Pimecrolimus-data not held*
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only -data not held*
- Tacrolimus ointment-data not held*
- Tralokinumab - <5**
- Upadacitinib - 56
- Nemolizumab - <5**

* Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

****** The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

***Patients are considered 'new patients initiated' on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation.**

e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025)

Response:

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

Response:

- 6 months to 5 - 0
- Age 6-11 - 7
- Age 12-17 - 15
- Age 18 and above – 210

Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

Response:

- Dupilumab -0
- Nemolizumab-0

Email: Foi.Team@Southerntrust.hscni.net